ALKS

Alkermes plc develops and commercializes innovative medicines for the treatment of serious mental illness and addiction. Headquartered in Dublin, Ireland, with U.S. operations based in Waltham, Massachusetts, the biopharmaceutical company employs approximately 2,000 people globally. Alkermes operates through two primary business segments: its proprietary commercial products and manufacturing and royalty-based revenues from partners. Key commercial products include VIVITROL for alcohol and opioid dependence, ARISTADA and ARISTADA INITIO for schizophrenia, and LYBALVI for schizophrenia and bipolar I disorder. The company also manufactures RISPERDAL CONSTA and INVEGA SUSTENNA/TRINZA for Johnson & Johnson, generating significant royalty income. Alkermes maintains advanced manufacturing facilities in Ohio, Pennsylvania, and Ireland, specializing in complex injectable formulations and proprietary drug delivery technologies. The company's LinkeRx platform technology enables extended-release formulations that improve medication adherence in chronic conditions. Alkermes reported revenues of approximately $1.3 billion in fiscal year 2023, with its commercial portfolio addressing significant unmet needs in central nervous system disorders. Recent strategic initiatives include advancing its pipeline of novel compounds targeting neuropsychiatric conditions and expanding its proprietary product portfolio. The company's manufacturing expertise and established commercial infrastructure in the neuroscience space position it as a notable mid-cap player in the biopharmaceutical sector.